187 related articles for article (PubMed ID: 28695864)
1. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy.
Dell'Atti L; Galosi AB
Asian J Androl; 2018; 20(1):15-18. PubMed ID: 28695864
[TBL] [Abstract][Full Text] [Related]
2. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.
Leone A; Gershman B; Rotker K; Butler C; Fantasia J; Miller A; Afiadata A; Amin A; Zhou A; Jiang Z; Sebo T; Mega A; Schiff S; Pareek G; Golijanin D; Yates J; Karnes RJ; Renzulli J
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):68-71. PubMed ID: 26857145
[TBL] [Abstract][Full Text] [Related]
3. Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm.
Ynalvez LA; Kosarek CD; Kerr PS; Mahmoud AM; Eyzaguirre EJ; Orihuela E; Sonstein JN; Williams SB
Int Urol Nephrol; 2018 Jan; 50(1):1-6. PubMed ID: 29064003
[TBL] [Abstract][Full Text] [Related]
4. Clinical strategy of repeat biopsy in patients with atypical small acinar proliferation (ASAP).
Kim H; Kim JK; Choe G; Hong SK
Sci Rep; 2021 Nov; 11(1):23143. PubMed ID: 34848744
[TBL] [Abstract][Full Text] [Related]
5. Racial Variation in the Outcome of Subsequent Prostate Biopsies in Men With an Initial Diagnosis of Atypical Small Acinar Proliferation.
Scott Libby R; Kramer JJ; Tue Nguyen HM; Feibus A; Thomas R; Silberstein JL
Clin Genitourin Cancer; 2017 Dec; 15(6):e995-e999. PubMed ID: 28566201
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer detection following diagnosis of atypical small acinar proliferation.
Ericson KJ; Wenger HC; Rosen AM; Kiriluk KJ; Gerber GS; Paner GP; Eggener SE
Can J Urol; 2017 Apr; 24(2):8714-8720. PubMed ID: 28436357
[TBL] [Abstract][Full Text] [Related]
7. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.
Scattoni V; Roscigno M; Freschi M; Dehò F; Raber M; Briganti A; Fantini G; Nava L; Montorsi F; Rigatti P
Arch Ital Urol Androl; 2005 Mar; 77(1):31-6. PubMed ID: 15906787
[TBL] [Abstract][Full Text] [Related]
8. Incidence, grade and distribution of prostate cancer following transperineal template-guided mapping biopsy in patients with atypical small acinar proliferation.
Merrick GS; Galbreath RW; Bennett A; Butler WM; Amamovich E
World J Urol; 2017 Jul; 35(7):1009-1013. PubMed ID: 27900453
[TBL] [Abstract][Full Text] [Related]
9. Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation.
Totaro A; Di Gianfrancesco L; Pinto F; Racioppi M; Palermo G; Campetella M; Santoro AA; Arbia G; Sacco E
Urologia; 2021 Aug; 88(3):194-199. PubMed ID: 33579180
[TBL] [Abstract][Full Text] [Related]
10. How many cores should be taken in a repeat biopsy on patients in whom atypical small acinar proliferation has been identified in an initial transrectal prostate biopsy?
Aglamis E; Kocaarslan R; Yucetas U; Toktas G; Ceylan C; Doluoglu OG; Unluer E
Int Braz J Urol; 2014; 40(5):605-12. PubMed ID: 25498271
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue.
Wiener S; Haddock P; Cusano J; Staff I; McLaughlin T; Wagner J
Urology; 2017 Dec; 110():161-165. PubMed ID: 28888752
[TBL] [Abstract][Full Text] [Related]
12. [Significance of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in prostate biopsy in China].
Yang MG; Xu ZQ
Zhonghua Nan Ke Xue; 2021 Sep; 27(9):798-802. PubMed ID: 34914255
[TBL] [Abstract][Full Text] [Related]
13. Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation.
Warlick C; Feia K; Tomasini J; Iwamoto C; Lindgren B; Risk M
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):255-9. PubMed ID: 25896264
[TBL] [Abstract][Full Text] [Related]
14. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer.
Iczkowski KA; Bassler TJ; Schwob VS; Bassler IC; Kunnel BS; Orozco RE; Bostwick DG
Urology; 1998 May; 51(5):749-57; discussion 757-8. PubMed ID: 9610588
[TBL] [Abstract][Full Text] [Related]
16. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
17. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.
García-Cruz E; Huguet J; Piqueras M; Márquez MP; Peri L; Izquierdo L; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
World J Urol; 2012 Jun; 30(3):361-5. PubMed ID: 21833558
[TBL] [Abstract][Full Text] [Related]
18. Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume.
Nakai Y; Tanaka N; Miyake M; Hori S; Tatsumi Y; Morizawa Y; Fujii T; Konishi N; Fujimoto K
Res Rep Urol; 2017; 9():187-193. PubMed ID: 29034221
[TBL] [Abstract][Full Text] [Related]
19. The place of prostate rebiopsy in the diagnosis of prostate cancer.
Vida OÁ; Pricop C; Loghin A; Chiuţu LC; Mártha O
Rom J Morphol Embryol; 2014; 55(3 Suppl):1161-6. PubMed ID: 25607400
[TBL] [Abstract][Full Text] [Related]
20. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
